Remedy Pharmaceuticals, Inc. develops small molecule drugs that target NCCa-ATP channels in acute central nervous system injuries, including traumatic brain injuries, strokes, and spinal cord injuries. Its RP-1127 is an intravenous version of glyburide, an inhibitor of NCCa-ATP channels that acts through antagonism of the type-1 sulfonylureareceptor. The company was founded in 2004 and is based in New York, New York.

Biotechnology

Health Care

Pharmaceutical

Remedy Pharmaceuticals

Remedy Pharmaceuticals' headquarters in New York, NY, United States

Description

People (2)

Sven Jacobson

david geliebter

Jobs